<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26124653</article-id><article-id pub-id-type="pmc">4476438</article-id><article-id pub-id-type="doi">10.2147/COPD.S87058</article-id><article-id pub-id-type="publisher-id">copd-10-1139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Inui</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref><xref ref-type="aff" rid="af2-copd-10-1139">2</xref><xref ref-type="corresp" rid="c1-copd-10-1139"/></contrib><contrib contrib-type="author"><name><surname>Matsushima</surname><given-names>Sayomi</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Shinpei</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Yasui</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Kono</surname><given-names>Masato</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Fujisawa</surname><given-names>Tomoyuki</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Enomoto</surname><given-names>Noriyuki</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Nakamura</surname><given-names>Yutaro</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib><contrib contrib-type="author"><name><surname>Toyoshima</surname><given-names>Mikio</given-names></name><xref ref-type="aff" rid="af3-copd-10-1139">3</xref></contrib><contrib contrib-type="author"><name><surname>Suda</surname><given-names>Takafumi</given-names></name><xref ref-type="aff" rid="af1-copd-10-1139">1</xref></contrib></contrib-group><aff id="af1-copd-10-1139"><label>1</label>Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Handayama, Hamamatsu, Japan</aff><aff id="af2-copd-10-1139"><label>2</label>Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Handayama, Hamamatsu, Japan</aff><aff id="af3-copd-10-1139"><label>3</label>Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Shougen-cho, Hamamatsu, Japan</aff><author-notes><corresp id="c1-copd-10-1139">Correspondence: Naoki Inui, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan, Tel +81 5 3435 2263, Fax +81 5 3435 2386, Email <email>inui@hama-med.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2015</year></pub-date><volume>10</volume><fpage>1139</fpage><lpage>1146</lpage><permissions><copyright-statement>&#x000a9; 2015 Inui et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2015</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>The forced oscillation technique (FOT) can measure respiratory mechanics and has attracted attention in chronic obstructive pulmonary disease (COPD). We aimed to evaluate the effects of only indacaterol and tiotropium monotherapies on airflow limitation and respiratory impedance. Pulmonary function tests, COPD assessment test (CAT), and multifrequency FOT with MostGraph-01 were performed at the beginning and after 8 weeks of treatment with indacaterol or tiotropium. The resistance index, resistance at 5 Hz (R5), resistance at 20 Hz (R20), reactance index, reactance at 5 Hz (X5), resonant frequency (Fres), and low-frequency reactance area (ALX) were determined at whole-breath, inspiratory, and expiratory phases. Eighty-two patients (mean age: 73 years; mean forced expiratory volume in 1 second (FEV<sub>1</sub>): 61.6%&#x000b1;19.0% predicted) were randomized to indacaterol or tiotropium treatment. Both bronchodilators improved airflow limitation, with mean trough improvements in FEV<sub>1</sub> of 165 mL and 80 mL in the indacaterol and tiotropium groups, respectively. The CAT score decreased in the indacaterol group (<italic>P</italic>&#x0003c;0.001; 11.2&#x000b1;6.6 to 7.5&#x000b1;5.6). Compared with tiotropium, indacaterol significantly improved FEV<sub>1</sub>, percent predicted FEV<sub>1</sub>, and CAT score (<italic>P</italic>=0.042, <italic>P</italic>=0.008, and <italic>P</italic>=0.027, respectively). For respiratory impedance, indacaterol and tiotropium changed R5, X5, Fres, and ALX at whole-breath, inspiratory, and expiratory phases. In the indacaterol group, the changes in R5, R5&#x02013;R20, X5, Fres, and ALX were significantly correlated with the changes in FEV<sub>1</sub>. The use of the FOT may enable the evaluation of the effects of bronchodilators in addition to FEV<sub>1</sub>-indicated therapeutic effects in COPD.</p></abstract><kwd-group><title>Keywords</title><kwd>chronic obstructive pulmonary disease</kwd><kwd>forced oscillation technique</kwd><kwd>indacaterol</kwd><kwd>monotherapy</kwd><kwd>MostGraph-01</kwd><kwd>reactance</kwd><kwd>resistance</kwd><kwd>tiotropium</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Chronic obstructive pulmonary disease (COPD) is an airway disease characterized by persistent, incompletely reversible, and commonly progressive airflow limitation.<xref rid="b1-copd-10-1139" ref-type="bibr">1</xref>,<xref rid="b2-copd-10-1139" ref-type="bibr">2</xref> The forced expiratory volume in 1 second (FEV<sub>1</sub>) obtained by spirometry evaluates the presence of airflow limitation and is currently used to diagnose and assess the severity of airflow limitation in COPD.<xref rid="b1-copd-10-1139" ref-type="bibr">1</xref>,<xref rid="b2-copd-10-1139" ref-type="bibr">2</xref> However, COPD is a complicated disorder with various pathophysiological changes<xref rid="b2-copd-10-1139" ref-type="bibr">2</xref>,<xref rid="b3-copd-10-1139" ref-type="bibr">3</xref> and the FEV<sub>1</sub> value has limits to fully represent the disease burden and diversity.<xref rid="b3-copd-10-1139" ref-type="bibr">3</xref> Other indices and methods, such as exacerbation rate, quality of life, symptoms assessed by the St George&#x02019;s Respiratory Questionnaire, modified Medical Research Council breathlessness scale, and COPD assessment test (CAT), and comorbidities, can be used for assessment of COPD.<xref rid="b1-copd-10-1139" ref-type="bibr">1</xref>,<xref rid="b3-copd-10-1139" ref-type="bibr">3</xref></p><p>For some years, the forced oscillation technique (FOT) has attracted attention in obstructive pulmonary diseases, asthma, and COPD.<xref rid="b4-copd-10-1139" ref-type="bibr">4</xref>&#x02013;<xref rid="b6-copd-10-1139" ref-type="bibr">6</xref> The FOT can measure respiratory mechanics during tidal breathing in an effort-independent manner with little cooperation by the subject. It can reflect the daily respiratory physiology and measure changes in response to therapy very sensitively.<xref rid="b4-copd-10-1139" ref-type="bibr">4</xref>,<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref>,<xref rid="b8-copd-10-1139" ref-type="bibr">8</xref> At present, two commercial multifrequency FOT devices, the impulse oscillation system<xref rid="b9-copd-10-1139" ref-type="bibr">9</xref> and MostGraph-01 (Chest M.I., Co., Ltd., Tokyo, Japan),<xref rid="b10-copd-10-1139" ref-type="bibr">10</xref> are available in Japan.</p><p>At present, inhaled anticholinergic and &#x003b2;<sub>2</sub>-agonist bronchodilators are central to the pharmacological interventions for COPD.<xref rid="b2-copd-10-1139" ref-type="bibr">2</xref> Current guidelines recommend a choice of bronchodilators depending on the availability, clinical response of symptom relief, and adverse effects,<xref rid="b1-copd-10-1139" ref-type="bibr">1</xref> and monotherapy with long-acting bronchodilators is used as maintenance therapy for patients with mild-to-severe COPD. Tiotropium is a long-acting muscarinic antagonist with a 24-hour persistent bronchodilator effect and is given once daily.<xref rid="b11-copd-10-1139" ref-type="bibr">11</xref> It has been reported to improve airflow limitation, symptoms, and quality of life, and reduce exacerbation and hospitalization.<xref rid="b12-copd-10-1139" ref-type="bibr">12</xref> Based on abundant evidence, tiotropium has been widely used as a first-line maintenance therapy. &#x003b2;<sub>2</sub>-agonists comprise another class of bronchodilators that affect &#x003b2;<sub>2</sub> receptors in bronchial smooth muscle and dilate the bronchi. Among the long-acting &#x003b2;<sub>2</sub>-agonists (LABAs), salmeterol and formoterol have an approximately 12-hour effect and require twice-daily administration.<xref rid="b13-copd-10-1139" ref-type="bibr">13</xref> Indacaterol is a novel LABA characterized by a 24-hour persistent bronchodilator effect. In addition, indacaterol has a rapid bronchodilator effect and was reported to increase FEV<sub>1</sub> even at 5 minutes postdose.<xref rid="b14-copd-10-1139" ref-type="bibr">14</xref> The relative potency of indacaterol on trough FEV<sub>1</sub> was reported to be 60&#x02013;100 mL greater than the trough FEV<sub>1</sub> measured at 12 hours after dosing with salmeterol or formoterol.<xref rid="b15-copd-10-1139" ref-type="bibr">15</xref></p><p>The present study compares tiotropium and indacaterol monotherapies in COPD patients. We evaluated the effects of these monotherapies on airflow limitation and respiratory impedance, assuming that these bronchodilators would have different properties on the large and the small airways. Although the FOT has already been used to assess COPD,<xref rid="b5-copd-10-1139" ref-type="bibr">5</xref>,<xref rid="b6-copd-10-1139" ref-type="bibr">6</xref>,<xref rid="b16-copd-10-1139" ref-type="bibr">16</xref>&#x02013;<xref rid="b20-copd-10-1139" ref-type="bibr">20</xref> to our knowledge, no previous studies have analyzed the therapeutic effects of indacaterol using this method. In addition, we investigated the relationships between the changes in FEV<sub>1</sub> and FOT parameters.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="subjects"><title>Patients</title><p>Patients with COPD who were aged &#x02265;40 years, had &#x02265;10 pack-years of smoking history, and had airflow limitation classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) I&#x02013;III (FEV<sub>1</sub> 30%&#x02013;80% of predicted value) were eligible for inclusion. The diagnosis and classification of COPD were performed according to the GOLD classification, which is based on the post-bronchodilator baseline lung function.<xref rid="b1-copd-10-1139" ref-type="bibr">1</xref> Patients were excluded from the study if they met the following exclusion criteria: two or more courses of oral corticosteroid or antibiotics in the previous 6 months; admission to hospital because of exacerbation in the previous 6 months; presence of large bulla or pneumothorax; severe chronic heart failure; or use of long-term oxygen therapy. We also excluded patients who exhibited significant bronchodilator reversibility (improvement of FEV<sub>1</sub> after inhalation of a short-acting bronchodilator of greater than 200 mL and 12% of the pre-bronchodilator FEV<sub>1</sub>) or had symptoms that were compatible with bronchial asthma.</p></sec><sec sec-type="methods"><title>Study design</title><p>This study was an open-label, randomized trial conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of each participating institution. All patients provided written informed consent. The trial was registered with the University Hospital Medical Information Network (UMIN) Clinical Trial Registry (UMIN ID 000009951).</p><p>After the initial evaluation, the eligible patients completed a &#x0003e;2-week baseline run-in period in which any bronchodilators including tiotropium (SPIRIVA HandiHaler; Boehringer Ingelheim, Ingelheim, Germany), regularly inhaled LABAs, inhaled corticosteroid, LABA/inhaled corticosteroid combinations, methylxanthine, and mucolytic agents were withdrawn. Following the run-in period, the patients were randomly assigned to a group receiving tiotropium (tiotropium treatment group) or a group receiving indacaterol (indacaterol treatment group) using a computer program. In the indacaterol treatment group, patients received indacaterol 150 &#x003bc;g once daily for 8 weeks using a Breezhaler device. In the tiotropium treatment group, tiotropium 18 &#x003bc;g was administered once daily for 8 weeks using a HandiHaler device. A rescue inhaled short-acting &#x003b2;<sub>2</sub>-agonist was used on demand to control symptoms throughout the study. Pulmonary function tests and the FOT were performed at the beginning and after 8 weeks of treatment. The FEV<sub>1</sub>, forced vital capacity (FVC), maximum midexpiratory flow rate (MMF), maximum expiratory flow rate at 50% FVC (V<sub>50</sub>) and 25% FVC (V<sub>25</sub>), and the inspiratory capacity were measured using an electric spirometer (Autospirometer System 7; Minato Medical Science Co., Ltd., Osaka, Japan). FVC and FEV<sub>1</sub> were expressed as percentages of predicted values according to the prediction equations of the Japanese Respiratory Society.<xref rid="b21-copd-10-1139" ref-type="bibr">21</xref> All measurements were taken before inhalation of the drugs in the morning and at least 1 hour after drinking and eating. Short-acting &#x003b2;<sub>2</sub>-agonists were not used for more than 12 hours before these tests in all cases. In addition, symptoms and health status were assessed using the CAT.</p></sec><sec><title>Measurement of respiratory impedance</title><p>Respiratory impedance was measured using a commercially available multifrequency FOT device (Most-Graph-01) as previously reported,<xref rid="b6-copd-10-1139" ref-type="bibr">6</xref>,<xref rid="b22-copd-10-1139" ref-type="bibr">22</xref>,<xref rid="b23-copd-10-1139" ref-type="bibr">23</xref> following standard recommendations.<xref rid="b4-copd-10-1139" ref-type="bibr">4</xref> Briefly, impulse oscillatory signals generated by a loud speaker at 0.25-second intervals were applied to the respiratory system through a mouthpiece during tidal breathing at rest. Mouth pressure and flow signals were measured and calculated, and the resistance and reactance properties against the oscillatory frequency were obtained. The FOT was performed before pulmonary function tests. During measurements, the subjects supported their cheeks firmly while sitting with their neck in a comfortable neutral posture. We evaluated the resistance at 5 Hz (R5), resistance at 20 Hz (R20), reactance at 5 Hz (X5), resonant frequency (Fres) where the reactance crosses zero and the elastic and inertial forces are equal in magnitude and opposite in sign, and low-frequency reactance area (ALX), which is the integral of reactance from 5 Hz to Fres. Each oscillatory index was expressed at whole-breath, inspiratory, and expiratory phases. The difference (&#x00394;) in each oscillatory index between the expiratory and inspiratory phases was calculated.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>The efficacies of indacaterol and tiotropium were assessed by the changes in the pulmonary function, FOT, and CAT. All values were analyzed using SPSS Statistics (version 21.0; IBM Corporation, Armonk, NY, USA). The Wilcoxon test was used for continuous variables and the chi-square test was used for categorized groups. Differences between the treatment groups and between the baseline and posttreatment values were analyzed by repeated-measures analysis of variance. Correlations between different parameters were evaluated using the Spearman&#x02019;s rank correlation coefficient test. Values of <italic>P</italic>&#x0003c;0.05 were considered to indicate significant differences. All data are described as mean &#x000b1; standard deviation, unless otherwise indicated.</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro|subjects"><title>Characteristics of the COPD patients</title><p>We recruited 82 patients with COPD (<xref ref-type="table" rid="t1-copd-10-1139">Table 1</xref>). The median age was 73 years (range: 52&#x02013;89 years). All patients were former or current smokers with a mean smoking history of 61.2 pack-years. The proportions of the GOLD classification stages according to airflow limitation severity were 24.4% in stage I, 41.5% in stage II, and 34.1% in stage III. No patients in stage IV were included. Most patients (81.7%) had already received tiotropium or LABA treatment and 14 patients had been treated with inhaled corticosteroid before enrollment in the study. There were no significant differences between the tiotropium and indacaterol treatment groups in the clinical features (<italic>P</italic>&#x02265;0.05 for each comparison; <xref ref-type="table" rid="t1-copd-10-1139">Tables 1</xref> and <xref ref-type="table" rid="t2-copd-10-1139">2</xref>). The mean FVC, FEV<sub>1</sub>, and inspiratory capacity in the indacaterol treatment group were 2.90 L, 1.59 L, and 1.97 L, respectively, and did not differ from those in the tiotropium treatment group (3.00 L, 1.62 L, and 2.00 L, respectively, <italic>P</italic>&#x02265;0.05 for each comparison). The CAT scores in the indacaterol treatment group and tiotropium treatment group were 11.2 and 11.0, respectively (<italic>P</italic>=0.686).</p></sec><sec><title>Lung function and COPD control</title><p>After 8 weeks of treatment with indacaterol or tiotropium, the pulmonary function test results were improved. In the indacaterol treatment group, FVC, FEV<sub>1</sub>, percentage of predicted FEV<sub>1</sub>, MMF, V<sub>50</sub>, and V<sub>25</sub> were significantly increased. In the tiotropium treatment group, FEV<sub>1</sub> and percent predicted FEV<sub>1</sub> were increased. There were no inspira-tory capacity changes in the indacaterol treatment group or tiotropium treatment group (<xref ref-type="table" rid="t2-copd-10-1139">Table 2</xref>). Compared with the differences between the baseline and posttreatment values in the tiotropium treatment group, the indacaterol treatment group showed significant larger increases in FEV<sub>1</sub> and percent predicted FEV<sub>1</sub> (<italic>P</italic>=0.041 and <italic>P</italic>=0.013, respectively). The CAT score was significantly decreased from 11.2&#x000b1;6.6 to 7.4&#x000b1;5.6 in the indacaterol treatment group (<italic>P</italic>&#x0003c;0.001). However, the CAT scores were nearly equal between baseline and 8 weeks of tiotropium treatment (11.0&#x000b1;7.4 and 10.0&#x000b1;7.3, respectively). Compared with tiotropium, 8 weeks of treatment with indacaterol significantly improved the CAT score (<italic>P</italic>=0.008). When the patients were divided using an increase of two points in the CAT score as the accepted minimum clinically important difference,<xref rid="b24-copd-10-1139" ref-type="bibr">24</xref> 23 and 13 patients showed CAT improvements of more than two points in the indacaterol treatment group and tiotropium treatment group, respectively.</p></sec><sec><title>Forced oscillation technique</title><p>The respiratory resistance and respiratory reactance at whole-breath, inspiratory, and expiratory phases and the expiratory&#x02013;inspiratory difference are summarized in <xref ref-type="table" rid="t3-copd-10-1139">Table 3</xref>. At the whole-breath phase, R5, Fres, and ALX were decreased and X5 was increased with statistical significance after 8 weeks of indacaterol treatment. In addition, R5&#x02013;R20 at the inspiratory phase was decreased in the indacaterol treatment group. At the expiratory phase, reactance parameters improved in the indacaterol treatment group. Similar FOT changes were observed in the tiotropium treatment group, in that R5, Fres, and ALX were decreased and X5 was increased at the whole-breath phase. However, there were no differences in these FOT changes between the indacaterol treatment group and tiotropium treatment group. Regarding the differences between the expiratory and inspiratory phases, the respiratory reactance parameters were significantly changed in both the indacaterol treatment and tiotropium treatment groups. &#x00394;X5 with indacaterol treatment and tiotropium treatment were 0.36 and 0.19, respectively, with no significant difference (<italic>P</italic>=0.465). In the comparisons with the changes in FEV<sub>1</sub>, the baseline R5 and X5 values at the whole-breath phase showed significant correlations (<italic>r</italic>=0.326, <italic>P</italic>=0.046 and <italic>r</italic>=&#x02212;0.330, <italic>P</italic>=0.043, respectively) only in the indacaterol treatment group. Next, we evaluated the relationships between the changes in FEV<sub>1</sub> and the FOT parameters after the treatments. The changes in R5, R5&#x02013;R20, X5, Fres, and ALX were significantly correlated with the changes in FEV<sub>1</sub> (R5: <italic>r</italic>=&#x02212;0.336, <italic>P</italic>=0.040; R5&#x02013;R20: <italic>r</italic>=&#x02212;0.345, <italic>P</italic>=0.034; X5: <italic>r</italic>=0.363, <italic>P</italic>=0.025; Fres: <italic>r</italic>=&#x02212;0.393, <italic>P</italic>=0.014; ALX: <italic>r</italic>=&#x02212;0.471, <italic>P</italic>=0.009) only in the indacaterol treatment group. Conversely, in the tiotropium treatment group, there were no correlations between the changes in FEV<sub>1</sub> and the FOT parameters.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study was designed to investigate the efficacies of only indacaterol and tiotropium monotherapies based on the airflow limitation, the impact on health status, and respiratory impedance in patients with mild-to-severe COPD. Both indacaterol and tiotropium improved the pulmonary function. Compared with tiotropium, indacaterol significantly increased FEV<sub>1</sub> and percent predicted FEV<sub>1</sub> and improved symptoms. We used a multifrequency FOT to assess the changes in respiratory resistance and respiratory reactance, and found that indacaterol and tiotropium predominantly improved the reactance components. There was no difference in changes of respiratory resistance and respiratory reactance parameters between the indacaterol and tiotropium treatment groups. These results suggest that indacaterol is an effective bronchodilator for COPD with distinct properties to tiotropium.</p><p>It has been recognized that indacaterol has at least noninferior effects on FEV<sub>1</sub> compared to tiotropium.<xref rid="b25-copd-10-1139" ref-type="bibr">25</xref>&#x02013;<xref rid="b28-copd-10-1139" ref-type="bibr">28</xref> In the present study, patients with indacaterol treatment showed greater improvement in their airflow limitation. The mean trough FEV<sub>1</sub> increased by 165 mL in the indacaterol treatment group, and was equivalent to or slightly higher than the values obtained in previous studies.<xref rid="b26-copd-10-1139" ref-type="bibr">26</xref>,<xref rid="b27-copd-10-1139" ref-type="bibr">27</xref> Conversely, tiotropium treatment induced an 80 mL increase in FEV<sub>1</sub>. The difference in improvement in FEV<sub>1</sub> between the indacaterol and tiotropium treatment groups can be attributed to several factors. First, bronchodilators dilate the airways with various potencies,<xref rid="b1-copd-10-1139" ref-type="bibr">1</xref>,<xref rid="b2-copd-10-1139" ref-type="bibr">2</xref> and the effects of indacaterol and tiotropium may differ according to the severity of COPD. Buhl et al<xref rid="b26-copd-10-1139" ref-type="bibr">26</xref> speculated that indacaterol was superior to tiotropium in moderate-or-less severe COPD patients in a subgroup analysis. In the present study, more than half of the patients had mild-and-moderate COPD and few patients had experienced exacerbation within the previous year; this may influence the greater improvement in FEV<sub>1</sub> in the indacaterol treatment group. Second, we observed the effects of the two bronchodilators during 8 weeks of treatment after a 2-week washout period. Although this administration period was sufficient to exert the maximal effects, the more rapid bronchodilation induced by indacaterol may contribute to the improvement of airflow limitation.<xref rid="b14-copd-10-1139" ref-type="bibr">14</xref> In addition, we withdrew all long-acting bronchodilators other than tiotropium and indacaterol, methylxanthine, and corticosteroids and compared only tiotropium and indacaterol monotherapies in patients with COPD. In previous studies comparing indacaterol and tiotropium,<xref rid="b25-copd-10-1139" ref-type="bibr">25</xref>,<xref rid="b26-copd-10-1139" ref-type="bibr">26</xref>,<xref rid="b28-copd-10-1139" ref-type="bibr">28</xref> about half of the patients included were receiving inhaled corticosteroids.</p><p>We assessed the effects of indacaterol and tiotropium on respiratory impedance using a new multifrequency FOT device, MostGraph-01. MostGraph-01 has three-dimensional color images and an added time axis to help visualize the respiratory cycle dependence. It has been reported that MostGraph-01 can assess the level of airflow limitation and bronchial reversibility in patients with asthma.<xref rid="b29-copd-10-1139" ref-type="bibr">29</xref>,<xref rid="b30-copd-10-1139" ref-type="bibr">30</xref> Similar to other FOT devices, such as the impulse oscillation system, MostGraph-01 can measure respiratory impedance at different frequencies in a noninvasive manner. Resistances are indices of airway caliber. Increased resistance in the small airways contributes to the airflow limitation in COPD.<xref rid="b31-copd-10-1139" ref-type="bibr">31</xref>,<xref rid="b32-copd-10-1139" ref-type="bibr">32</xref> As an imaginary part, reactance is supposed to reflect the elastic and inertial properties of the lung.<xref rid="b4-copd-10-1139" ref-type="bibr">4</xref> Using an impulse oscillation system, Abe et al<xref rid="b19-copd-10-1139" ref-type="bibr">19</xref> showed that treatment with tiotropium and another &#x003b2;<sub>2</sub>-agonist, tulobuterol, improved the resistance components R5 and R5&#x02013;R20 and reactance indices X5 and ALX. In the present study, R5, X5, Fres, and ALX were significantly changed by treatment with indacaterol and tiotropium. Respiratory reactance improved markedly with treatment not only at the whole-breath phase, but also at the inspiratory and expiratory phases. Although the meaning of the observations that bronchodilators predominantly improved reactance components remains unclear, reactance was reported to be more informative than resistance in explaining the changes in respiratory mechanics and airflow limitation severity in COPD.<xref rid="b16-copd-10-1139" ref-type="bibr">16</xref>,<xref rid="b18-copd-10-1139" ref-type="bibr">18</xref> These results confirmed that the FOT can measure changes in response to therapy in a sensitive manner.<xref rid="b4-copd-10-1139" ref-type="bibr">4</xref>,<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref>,<xref rid="b8-copd-10-1139" ref-type="bibr">8</xref></p><p>It is known that bronchodilators increase airway diameters, decrease airway resistance,<xref rid="b4-copd-10-1139" ref-type="bibr">4</xref> and make the pattern of airway obstruction more homogeneous in COPD patients.<xref rid="b17-copd-10-1139" ref-type="bibr">17</xref> The airway is broadly divided into two components: large and small airways. Although not well established, several parameters of spirometry and the FOT are considered in the assessment of physiological changes in the large and small airways separately.<xref rid="b19-copd-10-1139" ref-type="bibr">19</xref> Among these spirometric parameters, FEV<sub>1</sub> is not well suited to assess the abnormalities in the small airways<xref rid="b31-copd-10-1139" ref-type="bibr">31</xref> and is characterized as a large-airway parameter.<xref rid="b19-copd-10-1139" ref-type="bibr">19</xref> FVC and MMF are used as parameters in the assessment of small-airway function,<xref rid="b28-copd-10-1139" ref-type="bibr">28</xref> but the latter is influenced by large-airway obstruction and volume changes in patients with obstructive pulmonary diseases.<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref>,<xref rid="b27-copd-10-1139" ref-type="bibr">27</xref> Among FOT indices, R5 is considered as a marker of total resistance<xref rid="b20-copd-10-1139" ref-type="bibr">20</xref> or peripheral airway obstruction.<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref>,<xref rid="b18-copd-10-1139" ref-type="bibr">18</xref> With respect to reactance, Borrill et al<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref>,<xref rid="b8-copd-10-1139" ref-type="bibr">8</xref> showed that changes in X5 and Fres were related to small-airway bronchodilation, causing a decrease in hyperinflation and improvement in lung compliance. The phase III slope of the nitrogen (N<sub>2</sub>) washout curve in the single-breath washout test (delta N<sub>2</sub>) is sensitive and the preferred small-airway index.<xref rid="b31-copd-10-1139" ref-type="bibr">31</xref> Mikamo et al<xref rid="b33-copd-10-1139" ref-type="bibr">33</xref> found that Fres was an independent predictor of delta N<sub>2</sub>. In the present study, there were no differences in the changes in impedance parameters reflecting the small airways between the indacaterol and tiotropium treatment groups. Conversely, indacaterol treatment induced significantly larger increases in FEV<sub>1</sub> and percent predicted FEV<sub>1</sub> than did tiotropium treatment. In terms of spirometric and FOT parameters, our results may suggest that indacaterol provides greater bronchodilation in the large airways and that indacaterol and tiotropium have equivalent effects on small-airway bronchodilation. Because the vagus nerve mainly innervates the large airways and there is no vagal innervation in the small airways, there is a view that anticholinergic drugs are relatively effective in the central airways.<xref rid="b34-copd-10-1139" ref-type="bibr">34</xref> However, muscarinic receptors are located in all airways and those in the small airways are activated by extra-neuronal acetylcholine, which enables anticholinergic agents to bronchodilate in both the large and small airways.<xref rid="b35-copd-10-1139" ref-type="bibr">35</xref>,<xref rid="b36-copd-10-1139" ref-type="bibr">36</xref> Although the differences in potency and receptor binding affinity between indacaterol and tiotropium may induce the different bronchodilation in the large airways, more studies are needed to clarify the underlying mechanism.</p><p>Because FOT parameters may provide complementary information to spirometry,<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref> the relationships between FOT and preexisting parameters of airflow limitation and inflammation have been examined. Kolsum et al<xref rid="b18-copd-10-1139" ref-type="bibr">18</xref> estimated the relationships between FOT parameters and FEV<sub>1</sub> in 94 COPD patients with a mean percent predicted FEV<sub>1</sub> of 57.9% for 1 year. They found that R5, X5, and Fres were significantly associated with FEV<sub>1</sub>. In particular, X5 had the strongest association with FEV<sub>1</sub> and sequential changes in X5 were significantly related to FEV<sub>1</sub> changes over 1 year. In the present study, the changes in FEV<sub>1</sub> were significantly correlated with the changes in R5, R5&#x02013;R20, X5, Fres, and ALX at the whole-breath phase in the indacaterol treatment group. Conversely, in the tiotropium treatment group, there were no correlations between the changes in FEV<sub>1</sub> and the FOT parameters. For the parameters reflecting inflammation, Shirai et al<xref rid="b23-copd-10-1139" ref-type="bibr">23</xref> showed that differences of X5, Fres, and ALX between the expiratory and inspiratory phases were correlated with the alveolar nitric oxide concentration in patients with asthma. Williamson et al<xref rid="b20-copd-10-1139" ref-type="bibr">20</xref> suggested that the value of R5&#x02013;R20 was correlated with the corrected alveolar nitric oxide concentration in COPD patients. Spirometry and the FOT represent different aspects of respiratory physiology.<xref rid="b7-copd-10-1139" ref-type="bibr">7</xref> The use of the FOT may enable the assessment of the effects of bronchodilators other than FEV-indicated bronchodilation. Through investigations of the relationships with preexisting parameters, the significance of the FOT in the clinical setting will be increasingly clarified.</p><p>There are limitations of the present study. First, we withdrew all bronchodilators including tiotropium and LABAs for more than 2 weeks and performed a prospective randomized trial to evaluate the efficacies of indacaterol and tiotropium monotherapies. Unfortunately, however, it was not a blinded study. Second, although indacaterol showed good efficacy on symptoms and airflow limitation, a long-term follow-up period is necessary to assess the effects on exacerbation.</p><p>In conclusion, indacaterol significantly improved the airflow limitation and symptoms. For respiratory impedance, indacaterol and tiotropium improved the FOT parameters to similar extents. Both indacaterol and tiotropium enable once-daily administration, which can improve patient adherence with therapy, and monotherapy with these bronchodilators is effective for patients with COPD.</p></sec></body><back><ack><title>Acknowledgments</title><p>No financial support was provided for this study.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors declare no actual or potential conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-10-1139"><label>1</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab></person-group><source>Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html">http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html</ext-link></comment><date-in-citation>Accessed May 20, 2014</date-in-citation></element-citation></ref><ref id="b2-copd-10-1139"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><etal/><collab>Global Initiative for Chronic Obstructive Lung Disease</collab></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><issue>6</issue><fpage>532</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">17507545</pub-id></element-citation></ref><ref id="b3-copd-10-1139"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><etal/><collab>American Thoracic Society, European Respiratory Society Task Force on Outcomes of COPD</collab></person-group><article-title>Outcomes for COPD pharmacological trials: from lung function to biomarkers</article-title><source>Eur Respir J</source><year>2008</year><volume>31</volume><issue>2</issue><fpage>416</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">18238951</pub-id></element-citation></ref><ref id="b4-copd-10-1139"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostveen</surname><given-names>E</given-names></name><name><surname>MacLeod</surname><given-names>D</given-names></name><name><surname>Lorino</surname><given-names>H</given-names></name><etal/><collab>ERS Task Force on Respiratory Impedance Measurements</collab></person-group><article-title>The forced oscillation technique in clinical practice: methodology, recommendations and future developments</article-title><source>Eur Respir J</source><year>2003</year><volume>22</volume><issue>6</issue><fpage>1026</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">14680096</pub-id></element-citation></ref><ref id="b5-copd-10-1139"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paredi</surname><given-names>P</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name><name><surname>Alamen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2010</year><volume>65</volume><issue>3</issue><fpage>263</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">20335298</pub-id></element-citation></ref><ref id="b6-copd-10-1139"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Mikamo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma</article-title><source>COPD</source><year>2011</year><volume>8</volume><issue>6</issue><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">22149407</pub-id></element-citation></ref><ref id="b7-copd-10-1139"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrill</surname><given-names>ZL</given-names></name><name><surname>Houghton</surname><given-names>CM</given-names></name><name><surname>Woodcock</surname><given-names>AA</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name></person-group><article-title>Measuring bronchodilation in COPD clinical trials</article-title><source>Br J Clin Pharmacol</source><year>2005</year><volume>59</volume><issue>4</issue><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">15801931</pub-id></element-citation></ref><ref id="b8-copd-10-1139"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrill</surname><given-names>ZL</given-names></name><name><surname>Houghton</surname><given-names>CM</given-names></name><name><surname>Tal-Singer</surname><given-names>R</given-names></name><etal/></person-group><article-title>The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD</article-title><source>Br J Clin Pharmacol</source><year>2008</year><volume>65</volume><issue>2</issue><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">18251761</pub-id></element-citation></ref><ref id="b9-copd-10-1139"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellinckx</surname><given-names>J</given-names></name><name><surname>Cauberghs</surname><given-names>M</given-names></name><name><surname>De Boeck</surname><given-names>K</given-names></name><name><surname>Demedts</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of impulse oscillation system: comparison with forced oscillation technique and body plethysmography</article-title><source>Eur Respir J</source><year>2001</year><volume>18</volume><issue>3</issue><fpage>564</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">11589356</pub-id></element-citation></ref><ref id="b10-copd-10-1139"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurosawa</surname><given-names>H</given-names></name><name><surname>Ohishi</surname><given-names>J</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A new method to assess lung volume dependency of respiratory system resistance using forced oscillation</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>181</volume><fpage>A1240</fpage></element-citation></ref><ref id="b11-copd-10-1139"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Bantje</surname><given-names>TA</given-names></name><name><surname>Eland</surname><given-names>ME</given-names></name><name><surname>Korducki</surname><given-names>L</given-names></name><name><surname>Cornelissen</surname><given-names>PJ</given-names></name></person-group><article-title>A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group</article-title><source>Thorax</source><year>2000</year><volume>55</volume><issue>4</issue><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">10722768</pub-id></element-citation></ref><ref id="b12-copd-10-1139"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>S</given-names></name><etal/><collab>UPLIFT Study Investigators</collab></person-group><article-title>A 4-year trial of tiotropium in chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><issue>15</issue><fpage>1543</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">18836213</pub-id></element-citation></ref><ref id="b13-copd-10-1139"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharafkhaneh</surname><given-names>A</given-names></name><name><surname>Mattewal</surname><given-names>AS</given-names></name><name><surname>Abraham</surname><given-names>VM</given-names></name><name><surname>Dronavalli</surname><given-names>G</given-names></name><name><surname>Hanania</surname><given-names>NA</given-names></name></person-group><article-title>Budesonide/formoterol combination in COPD: a US perspective</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2010</year><volume>5</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">21037960</pub-id></element-citation></ref><ref id="b14-copd-10-1139"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelmeier</surname><given-names>C</given-names></name><name><surname>Ramos-Barbon</surname><given-names>D</given-names></name><name><surname>Jack</surname><given-names>D</given-names></name><etal/><collab>INTIME Study Investigators (INdacaterol &#x00026; TIotropium: Measuring Efficacy)</collab></person-group><article-title>Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium</article-title><source>Respir Res</source><year>2010</year><volume>11</volume><fpage>135</fpage><pub-id pub-id-type="pmid">20920365</pub-id></element-citation></ref><ref id="b15-copd-10-1139"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Chung</surname><given-names>KF</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><etal/><collab>INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators</collab></person-group><article-title>Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD</article-title><source>Thorax</source><year>2010</year><volume>65</volume><issue>6</issue><fpage>473</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">20522841</pub-id></element-citation></ref><ref id="b16-copd-10-1139"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Mango</surname><given-names>AM</given-names></name><name><surname>Lopes</surname><given-names>AJ</given-names></name><name><surname>Jansen</surname><given-names>JM</given-names></name><name><surname>Melo</surname><given-names>PL</given-names></name></person-group><article-title>Changes in respiratory mechanics with increasing degrees of airway obstruction in COPD: detection by forced oscillation technique</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><issue>3</issue><fpage>399</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">16115754</pub-id></element-citation></ref><ref id="b17-copd-10-1139"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellaca</surname><given-names>RL</given-names></name><name><surname>Pompilio</surname><given-names>PP</given-names></name><name><surname>Walker</surname><given-names>PP</given-names></name><name><surname>Duffy</surname><given-names>N</given-names></name><name><surname>Pedotti</surname><given-names>A</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name></person-group><article-title>Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD</article-title><source>Eur Respir J</source><year>2009</year><volume>33</volume><issue>6</issue><fpage>1329</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">19164347</pub-id></element-citation></ref><ref id="b18-copd-10-1139"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolsum</surname><given-names>U</given-names></name><name><surname>Borrill</surname><given-names>Z</given-names></name><name><surname>Roy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Impulse oscillometry in COPD: identification of measurements related to airway obstruction, airway conductance and lung volumes</article-title><source>Respir Med</source><year>2009</year><volume>103</volume><issue>1</issue><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">18760576</pub-id></element-citation></ref><ref id="b19-copd-10-1139"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Setoguchi</surname><given-names>Y</given-names></name><name><surname>Kono</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study</article-title><source>Pulm Pharmacol Ther</source><year>2011</year><volume>24</volume><issue>5</issue><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">21689775</pub-id></element-citation></ref><ref id="b20-copd-10-1139"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>PA</given-names></name><name><surname>Clearie</surname><given-names>K</given-names></name><name><surname>Menzies</surname><given-names>D</given-names></name><name><surname>Vaidyanathan</surname><given-names>S</given-names></name><name><surname>Lipworth</surname><given-names>BJ</given-names></name></person-group><article-title>Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD</article-title><source>Lung</source><year>2011</year><volume>189</volume><issue>2</issue><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">21174112</pub-id></element-citation></ref><ref id="b21-copd-10-1139"><label>21</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Japanese Respiratory Society</collab></person-group><source>Guidelines of Respiratory Function Tests: Spirometry, Flow-Volume Curve, and Diffusion Capacity of the Lung</source><publisher-loc>Tokyo</publisher-loc><publisher-name>Japanese Respiratory Society</publisher-name><year>2004</year><comment>in Japanese</comment></element-citation></ref><ref id="b22-copd-10-1139"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Mikamo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Respiratory mechanics measured by forced oscillation technique in combined pulmonary fibrosis and emphysema</article-title><source>Respir Physiol Neurobiol</source><year>2013</year><volume>185</volume><issue>2</issue><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">23117106</pub-id></element-citation></ref><ref id="b23-copd-10-1139"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Mikamo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Respiratory mechanics and peripheral airway inflammation and dysfunction in asthma</article-title><source>Clin Exp Allergy</source><year>2013</year><volume>43</volume><issue>5</issue><fpage>521</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">23600542</pub-id></element-citation></ref><ref id="b24-copd-10-1139"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kon</surname><given-names>SS</given-names></name><name><surname>Canavan</surname><given-names>JL</given-names></name><name><surname>Jones</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Minimum clinically important difference for the COPD Assessment Test: a prospective analysis</article-title><source>Lancet Respir Med</source><year>2014</year><volume>2</volume><issue>3</issue><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">24621681</pub-id></element-citation></ref><ref id="b25-copd-10-1139"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Fogarty</surname><given-names>C</given-names></name><name><surname>L&#x000f6;tvall</surname><given-names>J</given-names></name><etal/><collab>INHANCE Study Investigators</collab></person-group><article-title>Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium</article-title><source>Am J Respir Crit Care Med</source><year>2010</year><volume>182</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">20463178</pub-id></element-citation></ref><ref id="b26-copd-10-1139"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>LJ</given-names></name><name><surname>Disdier</surname><given-names>C</given-names></name><etal/><collab>INTENSITY Study Investigators</collab></person-group><article-title>Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD</article-title><source>Eur Respir J</source><year>2011</year><volume>38</volume><issue>4</issue><fpage>797</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">21622587</pub-id></element-citation></ref><ref id="b27-copd-10-1139"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cope</surname><given-names>S</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Jansen</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Comparative efficacy of long-acting bronchodilators for COPD &#x02013; a network meta-analysis</article-title><source>Respir Res</source><year>2013</year><volume>14</volume><issue>1</issue><fpage>100</fpage><pub-id pub-id-type="pmid">24093477</pub-id></element-citation></ref><ref id="b28-copd-10-1139"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decramer</surname><given-names>ML</given-names></name><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><etal/><collab>INVIGORATE Investigators</collab></person-group><article-title>Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study</article-title><source>Lancet Respir Med</source><year>2013</year><volume>1</volume><issue>7</issue><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">24461613</pub-id></element-citation></ref><ref id="b29-copd-10-1139"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuburai</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Tsurikisawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Use of forced oscillation technique to detect airflow limitations in adult Japanese asthmatics</article-title><source>Arerugi</source><year>2012</year><volume>61</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">22437728</pub-id></element-citation></ref><ref id="b30-copd-10-1139"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Habukawa</surname><given-names>C</given-names></name><name><surname>Kurosawa</surname><given-names>H</given-names></name><name><surname>Takemura</surname><given-names>T</given-names></name></person-group><article-title>Evaluation of airway responsiveness using colored three-dimensional analyses of a new forced oscillation technique in controlled asthmatic and nonasthmatic children</article-title><source>Respir Investig</source><year>2014</year><volume>52</volume><fpage>57</fpage><lpage>64</lpage></element-citation></ref><ref id="b31-copd-10-1139"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contoli</surname><given-names>M</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><etal/></person-group><article-title>The small airways and distal lung compartment in asthma and COPD: a time for reappraisal</article-title><source>Allergy</source><year>2010</year><volume>65</volume><issue>2</issue><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">19909298</pub-id></element-citation></ref><ref id="b32-copd-10-1139"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturton</surname><given-names>G</given-names></name><name><surname>Persson</surname><given-names>C</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Small airways: an important but neglected target in the treatment of obstructive airway diseases</article-title><source>Trends Pharmacol Sci</source><year>2008</year><volume>29</volume><issue>7</issue><fpage>340</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">18514920</pub-id></element-citation></ref><ref id="b33-copd-10-1139"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikamo</surname><given-names>M</given-names></name><name><surname>Shirai</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><etal/></person-group><article-title>Predictors of phase III slope of nitrogen single-breath washout in COPD</article-title><source>Respir Physiol Neurobiol</source><year>2013</year><volume>189</volume><issue>1</issue><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">23816601</pub-id></element-citation></ref><ref id="b34-copd-10-1139"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rennard</surname><given-names>SI</given-names></name></person-group><article-title>Combination bronchodilator therapy in COPD</article-title><source>Chest</source><year>1995</year><volume>107</volume><issue>5</issue><fpage>171S</fpage><lpage>175S</lpage><pub-id pub-id-type="pmid">7743822</pub-id></element-citation></ref><ref id="b35-copd-10-1139"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Distribution of receptor targets in the lung</article-title><source>Proc Am Thorac Soc</source><year>2004</year><volume>1</volume><issue>4</issue><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">16113456</pub-id></element-citation></ref><ref id="b36-copd-10-1139"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>S</given-names></name><name><surname>Cote</surname><given-names>C</given-names></name></person-group><article-title>Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease</article-title><source>Curr Clin Pharmacol</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>48</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">21235463</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-copd-10-1139" position="float"><label>Table 1</label><caption><p>Characteristics of patients with COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Indacaterol treatment group (n=41)</th><th valign="top" align="left" rowspan="1" colspan="1">Tiotropium treatment group (n=41)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, years</td><td valign="top" align="left" rowspan="1" colspan="1">72.2 (8.4)</td><td valign="top" align="left" rowspan="1" colspan="1">72.8 (9.0)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Sex</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">39 (95.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (100)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="left" rowspan="1" colspan="1">2 (4.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Smoking status</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Former smoker</td><td valign="top" align="left" rowspan="1" colspan="1">33 (80.5)</td><td valign="top" align="left" rowspan="1" colspan="1">37 (90.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Current smoker</td><td valign="top" align="left" rowspan="1" colspan="1">8 (19.5)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (9.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Pack-years</td><td valign="top" align="left" rowspan="1" colspan="1">61.8 (53.1)</td><td valign="top" align="left" rowspan="1" colspan="1">58.7 (31.1)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">GOLD criteria</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;I/II/III/IV</td><td valign="top" align="left" rowspan="1" colspan="1">9/19/13/0</td><td valign="top" align="left" rowspan="1" colspan="1">11/15/15/0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">22.2 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">22.7 (3.1)</td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1">Pulmonary function tests</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;FVC (L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.90 (0.64)</td><td valign="top" align="left" rowspan="1" colspan="1">3.00 (0.83)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub> (L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.59 (0.52)</td><td valign="top" align="left" rowspan="1" colspan="1">1.62 (0.66)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, % predicted</td><td valign="top" align="left" rowspan="1" colspan="1">62.0 (19.5)</td><td valign="top" align="left" rowspan="1" colspan="1">61.1 (18.7)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC (%)</td><td valign="top" align="left" rowspan="1" colspan="1">54.5 (13.1)</td><td valign="top" align="left" rowspan="1" colspan="1">54.1 (14.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Inspiratory capacity (L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.97 (0.47)</td><td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.59)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;MMF (L/s)</td><td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.63)</td><td valign="top" align="left" rowspan="1" colspan="1">0.75 (0.47)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;V<sub>50</sub> (L/s)</td><td valign="top" align="left" rowspan="1" colspan="1">1.07 (0.84)</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (0.62)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;V<sub>25</sub> (L/s)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.27)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.16)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CAT</td><td valign="top" align="left" rowspan="1" colspan="1">11.2 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11.0 (7.4)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-10-1139"><p><bold>Note:</bold> Data are expressed as number (%) or mean (SD).</p></fn><fn id="tfn2-copd-10-1139"><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; FVC, forced vital capacity; FEV<sub>1</sub>, forced expiratory volume in 1 second; MMF, maximum midexpiratory flow rate; V<sub>50</sub>, maximum expiratory flow rate at 50% FVC; V<sub>25</sub>, maximum expiratory flow rate at 25% FVC; CAT, COPD assessment test; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-10-1139" position="float"><label>Table 2</label><caption><p>Pulmonary function and COPD assessment scores before and after indacaterol and tiotropium treatment for 8 weeks</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">Indacaterol treatment
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Tiotropium treatment
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1">Comparison between treatment<xref ref-type="table-fn" rid="tfn4-copd-10-1139">&#x02020;</xref></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Baseline</th><th valign="top" align="left" rowspan="1" colspan="1">After</th><th valign="top" align="left" rowspan="1" colspan="1">Change</th><th valign="top" align="left" rowspan="1" colspan="1">Baseline</th><th valign="top" align="left" rowspan="1" colspan="1">After</th><th valign="top" align="left" rowspan="1" colspan="1">Change</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">FVC (L)</td><td valign="top" align="left" rowspan="1" colspan="1">2.90 (0.64)</td><td valign="top" align="left" rowspan="1" colspan="1">3.06 (0.61)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.13 (0.26)</td><td valign="top" align="left" rowspan="1" colspan="1">3.00 (0.83)</td><td valign="top" align="left" rowspan="1" colspan="1">3.07 (0.78)</td><td valign="top" align="left" rowspan="1" colspan="1">0.07 (0.31)</td><td valign="top" align="left" rowspan="1" colspan="1">0.363</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.59 (0.52)</td><td valign="top" align="left" rowspan="1" colspan="1">1.76 (0.53)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.16 (0.19)</td><td valign="top" align="left" rowspan="1" colspan="1">1.62 (0.66)</td><td valign="top" align="left" rowspan="1" colspan="1">1.70 (0.67)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.08 (0.18)</td><td valign="top" align="left" rowspan="1" colspan="1">0.041<xref ref-type="table-fn" rid="tfn6-copd-10-1139">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>, % predicted</td><td valign="top" align="left" rowspan="1" colspan="1">62.0 (19.5)</td><td valign="top" align="left" rowspan="1" colspan="1">68.6 (18.3)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">7.05 (8.00)</td><td valign="top" align="left" rowspan="1" colspan="1">61.1 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">63.6 (19.2)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.56 (7.64)</td><td valign="top" align="left" rowspan="1" colspan="1">0.013<xref ref-type="table-fn" rid="tfn6-copd-10-1139">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC (%)</td><td valign="top" align="left" rowspan="1" colspan="1">54.5 (13.1)</td><td valign="top" align="left" rowspan="1" colspan="1">57.9 (13.3)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3.43 (4.55)</td><td valign="top" align="left" rowspan="1" colspan="1">54.1 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">55.7 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1.54 (7.36)</td><td valign="top" align="left" rowspan="1" colspan="1">0.156</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inspiratory capacity (L)</td><td valign="top" align="left" rowspan="1" colspan="1">1.97 (0.47)</td><td valign="top" align="left" rowspan="1" colspan="1">2.07 (0.48)</td><td valign="top" align="left" rowspan="1" colspan="1">0.06 (0.24)</td><td valign="top" align="left" rowspan="1" colspan="1">2.00 (0.59)</td><td valign="top" align="left" rowspan="1" colspan="1">1.96 (0.58)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.04 (0.38)</td><td valign="top" align="left" rowspan="1" colspan="1">0.154</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MMF (L/s)</td><td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.63)</td><td valign="top" align="left" rowspan="1" colspan="1">0.89 (0.72)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.15 (0.27)</td><td valign="top" align="left" rowspan="1" colspan="1">0.75 (0.47)</td><td valign="top" align="left" rowspan="1" colspan="1">0.88 (0.63)</td><td valign="top" align="left" rowspan="1" colspan="1">0.13 (0.45)</td><td valign="top" align="left" rowspan="1" colspan="1">0.732</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">V<sub>50</sub> (L/s)</td><td valign="top" align="left" rowspan="1" colspan="1">1.07 (0.84)</td><td valign="top" align="left" rowspan="1" colspan="1">1.30 (0.91)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.23 (0.33)</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (0.62)</td><td valign="top" align="left" rowspan="1" colspan="1">1.20 (0.78)</td><td valign="top" align="left" rowspan="1" colspan="1">0.11 (0.34)</td><td valign="top" align="left" rowspan="1" colspan="1">0.144</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">V<sub>25</sub> (L/s)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.27)</td><td valign="top" align="left" rowspan="1" colspan="1">0.36 (0.32)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.05 (0.13)</td><td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.16)</td><td valign="top" align="left" rowspan="1" colspan="1">0.33 (0.18)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02 (0.10)</td><td valign="top" align="left" rowspan="1" colspan="1">0.309</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAT</td><td valign="top" align="left" rowspan="1" colspan="1">11.2 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">7.5 (5.6)<xref ref-type="table-fn" rid="tfn5-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.54 (4.67)</td><td valign="top" align="left" rowspan="1" colspan="1">11.0 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">10.0 (7.3)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.90 (3.63)</td><td valign="top" align="left" rowspan="1" colspan="1">0.008<xref ref-type="table-fn" rid="tfn6-copd-10-1139">**</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-copd-10-1139"><p><bold>Notes:</bold> Values are expressed as mean (SD).</p></fn><fn id="tfn4-copd-10-1139"><label>&#x02020;</label><p>Comparison of changes in indacaterol treatment and tiotropium treatment.</p></fn><fn id="tfn5-copd-10-1139"><label>*</label><p><italic>P</italic>&#x0003c;0.05 compared with baseline.</p></fn><fn id="tfn6-copd-10-1139"><label>**</label><p><italic>P</italic>&#x0003c;0.05, significant difference between changes with indacaterol treatment and tiotropium treatment.</p></fn><fn id="tfn7-copd-10-1139"><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease; FVC, forced vital capacity; FEV<sub>1</sub>, forced expiratory volume in 1 second; MMF, maximum midexpiratory flow rate; V<sub>50</sub>, maximum expiratory flow rate at 50% FVC; V<sub>25</sub>, maximum expiratory flow rate at 25% FVC; CAT, COPD assessment test; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-copd-10-1139" position="float"><label>Table 3</label><caption><p>Respiratory resistance and respiratory reactance at whole-breath, inspiratory, and expiratory phases, and differences between inspiratory and expiratory phases</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">Indacaterol
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Tiotropium
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1">Comparison between treatment<xref ref-type="table-fn" rid="tfn9-copd-10-1139">**</xref></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Baseline</th><th valign="top" align="left" rowspan="1" colspan="1">After</th><th valign="top" align="left" rowspan="1" colspan="1">Change</th><th valign="top" align="left" rowspan="1" colspan="1">Baseline</th><th valign="top" align="left" rowspan="1" colspan="1">After</th><th valign="top" align="left" rowspan="1" colspan="1">Change</th></tr></thead><tbody><tr><td colspan="8" valign="top" align="left" rowspan="1">Whole-breath</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5</td><td valign="top" align="left" rowspan="1" colspan="1">3.38 (1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">3.14 (1.05)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.21 (1.01)</td><td valign="top" align="left" rowspan="1" colspan="1">3.44 (1.31)</td><td valign="top" align="left" rowspan="1" colspan="1">2.97 (1.18)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.46 (1.08)</td><td valign="top" align="left" rowspan="1" colspan="1">0.280</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R20</td><td valign="top" align="left" rowspan="1" colspan="1">2.67 (0.79)</td><td valign="top" align="left" rowspan="1" colspan="1">2.56 (0.77)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.07 (0.66)</td><td valign="top" align="left" rowspan="1" colspan="1">2.66 (0.85)</td><td valign="top" align="left" rowspan="1" colspan="1">2.34 (0.82)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.32 (0.79)</td><td valign="top" align="left" rowspan="1" colspan="1">0.131</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5&#x02013;R20</td><td valign="top" align="left" rowspan="1" colspan="1">0.70 (0.54)</td><td valign="top" align="left" rowspan="1" colspan="1">0.59 (0.45)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.12 (0.58)</td><td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.55)</td><td valign="top" align="left" rowspan="1" colspan="1">0.64 (0.50)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.13 (0.46)</td><td valign="top" align="left" rowspan="1" colspan="1">0.957</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;X5</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.24 (1.14)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.74 (0.59)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.72)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.49 (1.50)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.99 (1.11)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.50 (1.00)</td><td valign="top" align="left" rowspan="1" colspan="1">0.711</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fres</td><td valign="top" align="left" rowspan="1" colspan="1">13.78 (5.99)</td><td valign="top" align="left" rowspan="1" colspan="1">10.84 (4.39)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.86 (4.89)</td><td valign="top" align="left" rowspan="1" colspan="1">14.80 (6.75)</td><td valign="top" align="left" rowspan="1" colspan="1">12.22 (5.68)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.58 (4.13)</td><td valign="top" align="left" rowspan="1" colspan="1">0.782</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;ALX</td><td valign="top" align="left" rowspan="1" colspan="1">9.15 (10.27)</td><td valign="top" align="left" rowspan="1" colspan="1">4.44 (5.22)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.30 (7.50)</td><td valign="top" align="left" rowspan="1" colspan="1">12.34 (16.21)</td><td valign="top" align="left" rowspan="1" colspan="1">7.13 (9.72)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.22 (11.23)</td><td valign="top" align="left" rowspan="1" colspan="1">0.673</td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1">Expiratory phase</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5</td><td valign="top" align="left" rowspan="1" colspan="1">3.68 (1.35)</td><td valign="top" align="left" rowspan="1" colspan="1">3.53 (1.25)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.13 (1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">3.77 (1.41)</td><td valign="top" align="left" rowspan="1" colspan="1">2.30 (1.38)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.48 (1.29)</td><td valign="top" align="left" rowspan="1" colspan="1">0.220</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R20</td><td valign="top" align="left" rowspan="1" colspan="1">2.81 (0.86)</td><td valign="top" align="left" rowspan="1" colspan="1">2.75 (0.87)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.02 (0.71)</td><td valign="top" align="left" rowspan="1" colspan="1">2.82 (0.91)</td><td valign="top" align="left" rowspan="1" colspan="1">2.48 (0.87)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.34 (0.85)</td><td valign="top" align="left" rowspan="1" colspan="1">0.077</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5&#x02013;R20</td><td valign="top" align="left" rowspan="1" colspan="1">0.87 (0.65)</td><td valign="top" align="left" rowspan="1" colspan="1">0.78 (0.58)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.11 (0.73)</td><td valign="top" align="left" rowspan="1" colspan="1">0.94 (0.62)</td><td valign="top" align="left" rowspan="1" colspan="1">0.81 (0.70)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.13 (0.68)</td><td valign="top" align="left" rowspan="1" colspan="1">0.878</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;X5</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.51 (1.56)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.85 (0.82)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.60 (1.06)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.98 (2.33)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.24 (1.46)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.74 (1.88)</td><td valign="top" align="left" rowspan="1" colspan="1">0.682</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fres</td><td valign="top" align="left" rowspan="1" colspan="1">14.91 (7.02)</td><td valign="top" align="left" rowspan="1" colspan="1">11.33 (5.40)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.52 (5.80)</td><td valign="top" align="left" rowspan="1" colspan="1">16.35 (8.10)</td><td valign="top" align="left" rowspan="1" colspan="1">13.18 (7.03)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.17 (5.20)</td><td valign="top" align="left" rowspan="1" colspan="1">0.772</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;ALX</td><td valign="top" align="left" rowspan="1" colspan="1">12.13 (14.69)</td><td valign="top" align="left" rowspan="1" colspan="1">5.67 (7.78)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.06 (11.05)</td><td valign="top" align="left" rowspan="1" colspan="1">17.19 (25.14)</td><td valign="top" align="left" rowspan="1" colspan="1">10.68 (14.96)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;6.51 (17.99)</td><td valign="top" align="left" rowspan="1" colspan="1">0.893</td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1">Inspiratory phase</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5</td><td valign="top" align="left" rowspan="1" colspan="1">3.09 (0.76)</td><td valign="top" align="left" rowspan="1" colspan="1">2.76 (0.95)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.28 (0.88)</td><td valign="top" align="left" rowspan="1" colspan="1">3.09 (1.28)</td><td valign="top" align="left" rowspan="1" colspan="1">2.65 (1.10)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.45 (1.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.451</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R20</td><td valign="top" align="left" rowspan="1" colspan="1">2.56 (0.76)</td><td valign="top" align="left" rowspan="1" colspan="1">2.37 (0.73)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.15 (0.59)</td><td valign="top" align="left" rowspan="1" colspan="1">2.48 (0.85)</td><td valign="top" align="left" rowspan="1" colspan="1">2.19 (0.81)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.29 (0.79)</td><td valign="top" align="left" rowspan="1" colspan="1">0.380</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5&#x02013;R20</td><td valign="top" align="left" rowspan="1" colspan="1">0.53 (0.47)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38 (0.36)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.15 (0.47)</td><td valign="top" align="left" rowspan="1" colspan="1">0.61 (0.52)</td><td valign="top" align="left" rowspan="1" colspan="1">0.46 (0.45)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.15 (0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.986</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;X5</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.94 (0.78)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.64 (0.42)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.23 (0.46)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.00 (0.76)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.56 (1.12)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.44 (1.05)</td><td valign="top" align="left" rowspan="1" colspan="1">0.262</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fres</td><td valign="top" align="left" rowspan="1" colspan="1">12.64 (5.23)</td><td valign="top" align="left" rowspan="1" colspan="1">10.04 (3.22)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.50 (4.26)</td><td valign="top" align="left" rowspan="1" colspan="1">13.35 (5.85)</td><td valign="top" align="left" rowspan="1" colspan="1">11.27 (4.62)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.08 (3.63)</td><td valign="top" align="left" rowspan="1" colspan="1">0.634</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;ALX</td><td valign="top" align="left" rowspan="1" colspan="1">6.08 (6.46)</td><td valign="top" align="left" rowspan="1" colspan="1">3.19 (3.06)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.46 (4.32)</td><td valign="top" align="left" rowspan="1" colspan="1">6.97 (7.81)</td><td valign="top" align="left" rowspan="1" colspan="1">3.47 (7.57)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.49 (8.08)</td><td valign="top" align="left" rowspan="1" colspan="1">0.486</td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1">Differences between inspiratory and expiratory phases</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5</td><td valign="top" align="left" rowspan="1" colspan="1">0.59 (0.64)</td><td valign="top" align="left" rowspan="1" colspan="1">0.76 (0.72)</td><td valign="top" align="left" rowspan="1" colspan="1">0.15 (0.60)</td><td valign="top" align="left" rowspan="1" colspan="1">0.68 (0.66)</td><td valign="top" align="left" rowspan="1" colspan="1">0.64 (0.78)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.03 (0.86)</td><td valign="top" align="left" rowspan="1" colspan="1">0.279</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R20</td><td valign="top" align="left" rowspan="1" colspan="1">0.24 (0.42)</td><td valign="top" align="left" rowspan="1" colspan="1">0.38 (0.46)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.13 (0.36)</td><td valign="top" align="left" rowspan="1" colspan="1">0.33 (0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30 (0.36)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.03 (0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.062</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;R5&#x02013;R20</td><td valign="top" align="left" rowspan="1" colspan="1">0.34 (0.33)</td><td valign="top" align="left" rowspan="1" colspan="1">0.39 (0.36)</td><td valign="top" align="left" rowspan="1" colspan="1">0.02 (0.37)</td><td valign="top" align="left" rowspan="1" colspan="1">0.34 (0.41)</td><td valign="top" align="left" rowspan="1" colspan="1">0.37 (0.57)</td><td valign="top" align="left" rowspan="1" colspan="1">0.03 (0.61)</td><td valign="top" align="left" rowspan="1" colspan="1">0.942</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;X5</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.55 (0.97)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.20 (0.56)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.36 (0.78)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.97 (1.75)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;0.77 (1.66)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.19 (1.72)</td><td valign="top" align="left" rowspan="1" colspan="1">0.597</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Fres</td><td valign="top" align="left" rowspan="1" colspan="1">2.27 (3.11)</td><td valign="top" align="left" rowspan="1" colspan="1">1.29 (3.44)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.02 (2.97)</td><td valign="top" align="left" rowspan="1" colspan="1">2.90 (3.73)</td><td valign="top" align="left" rowspan="1" colspan="1">1.91 (3.49)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;1.00 (3.33)</td><td valign="top" align="left" rowspan="1" colspan="1">0.968</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;ALX</td><td valign="top" align="left" rowspan="1" colspan="1">5.96 (9.82)</td><td valign="top" align="left" rowspan="1" colspan="1">2.50 (5.56)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.48 (7.70)</td><td valign="top" align="left" rowspan="1" colspan="1">10.48 (19.61)</td><td valign="top" align="left" rowspan="1" colspan="1">7.32 (14.05)<xref ref-type="table-fn" rid="tfn8-copd-10-1139">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;3.17 (16.17)</td><td valign="top" align="left" rowspan="1" colspan="1">0.913</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn8-copd-10-1139"><label>*</label><p><italic>P</italic>&#x0003c;0.05 compared with baseline.</p></fn><fn id="tfn9-copd-10-1139"><label>**</label><p>Comparison of changes in indacaterol treatment and tiotropium treatment. Values are expressed as mean (SD).</p></fn><fn id="tfn10-copd-10-1139"><p><bold>Abbreviations:</bold> R5, resistance at 5 Hz; R20, resistance at 20 Hz; X5, reactance index, reactance at 5 Hz; Fres, resonant frequency; ALX, low-frequency reactance area; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>